Sionna Therapeutics, Inc.
NASDAQ:SIONBiotechnology
+$0.68 today
- Market cap
- $134.35M
- Beta
- 1.29
- P/E (TTM)
- -19.7
- EPS (TTM)
- -$1.90
Volume 0.52M
Average 0.39M
SION Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Sionna Therapeutics, Inc.NASDAQ: SION
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $154K fell 64.3% year over year, behind the +41.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 69.4% from the prior quarter. Over 3 fiscal years it compounded at +74.4% a year.
Context
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -64.3% toward the trailing-twelve-month pace of +41.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 647K USD
- Year-over-year change
- -3.1%
- 3-year CAGR
- +74.4%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 647K | -3.1% |
| FY2024 | 2024-12-31 | 668K | +14.6% |
| FY2023 | 2023-12-31 | 583K | +377.9% |
| FY2022 | 2022-12-31 | 122K | — |
Depreciation & Amortization vs competitors
How SION compares with its peers on the latest reported figures
- SION's LTM Mar 2026 depreciation & amortization of $1.32M is the 10th highest of the 11 companies compared; the peer median is $3.55M.
- Its year-over-year change of +41.9% is the 3rd highest of 11, against a peer median of -0.2%.
- Over three fiscal years its annual growth of +74.4% compares with a peer median of +5.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $32.16M | -7.6% | -4.5% | 47.4% | |
| LTM Mar 2026 | $12.61M | +0.4% | -1.4% | 4.0% | |
| LTM Jun 2026 | $10.67M | +22.9% | +92.7% | — | |
| LTM Sep 2026 | $8.21M | -35.8% | -2.5% | 3.1% | |
| LTM Sep 2026 | $3.73M | +10.4% | +5.3% | 3333.9% | |
| LTM Mar 2026 | $3.37M | +51.2% | +38.8% | 0.8% | |
| LTM Sep 2026 | $2.69M | -3.0% | +67.3% | — | |
| LTM Mar 2026 | $2.16M | -28.6% | -14.3% | 10.8% | |
| LTM Mar 2026 | $2.03M | -0.8% | +34.1% | 9.4% | |
| LTM Mar 2026 | $1.32M | +41.9% | +74.4% | — | |
| LTM Jun 2026 | $536K | +89.4% | — | — | |
| Peer median (excluding SION) | $3.55M | -0.2% | +5.3% | 9.4% | |
Competitors are the stored peer set for SION. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 668K | 647K |
| Gross Profit | 0 | 0 | (668K) | (647K) |
| Gross Margin | — | — | — | — |
| Research & Development | 34.61M | 40.63M | 57.29M | 60.26M |
| Selling, General & Admin | 6.77M | 9.71M | 13.27M | 28.72M |
| Operating Expenses | 41.37M | 50.33M | 69.89M | 88.34M |
| Depreciation & Amortization | 122K | 583K | 668K | 647K |
| EBITDA | (40.12M) | (46.68M) | (61.02M) | (74.62M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (41.37M) | (50.33M) | (70.56M) | (88.98M) |
| Operating Margin | — | — | — | — |
| Interest Income | 1.13M | 2.77M | 8.17M | 13.3M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 1.13M | 3.07M | 8.87M | 13.71M |
| Income Before Tax | (40.24M) | (47.26M) | (61.69M) | (75.27M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (40.24M) | (47.26M) | (61.69M) | (75.27M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.91) | (1.07) | (1.40) | (1.88) |
| EPS (Diluted) | (0.91) | (1.07) | (1.40) | (1.88) |
| Weighted Avg Shares | 44.12M | 44.12M | 44.12M | 39.96M |
| Weighted Avg Shares (Diluted) | 44.12M | 44.12M | 44.12M | 39.96M |
Sionna Therapeutics, Inc.
NASDAQ:SION
Intrinsic Alpha fair value
Locked
Current Price
$2.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.